Markets
TOPSHOT-US-POLITICS-TRUMP-BIDEN
President Joe Biden shakes hands with President-elect Donald Trump during a meeting in the Oval Office (Saul Loeb/Getty Images)
second time’s the charm?

Fund managers with $500 billion are piling into the same “Trump trades” that mostly fizzled out last time

I guess there’s a reason that they call them “Trump trades,” not “Trump investments.”

Luke Kawa

The knee-jerk market reaction to Donald Trump’s victory in the presidential election — US equities and the dollar outperforming their peers — has been a case of déjà vu all over again.

And fund managers with $565 billion in assets are diving into so-called “Trump trades” in earnest: the same things that everyone bought the last time.

Bank of America’s closely watched global fund-manager survey had an interesting wrinkle this month: with responses received between November 1 and 7, they were able to isolate how much investors’ views changed immediately following the US vote.

The common theme from these respondents, who collectively manage $565 billion, was as pro-US as a bald eagle eating apple pie.

Those surveyed before the election thought US and global stocks would be about neck-and-neck in 2025; now, American equities are decisively the preferred option.

US stocks Nov 24 FMS
Source: BofA

The US dollar? The top pick to outperform in the world of foreign exchange.

Foreign exchange FMS Nov 2024
Source: BofA

And it’s now conventional wisdom within this group that small caps, which are more sensitive to domestic growth and tax changes, will outperform the S&P 500.

Small vs large BofA FMS Nov 24
Source: BofA

Let’s evaluate how all of these trades fared through Trump 1.0.

Small caps proceeded to underperform large caps by more than 20% from Election Day 2016 through Election Day 2020, even after getting off to a 10% lead within a month of Trump’s surprising 2016 victory. Heck, US small caps barely outperformed developed-market small caps as a whole over this period despite superior US economic growth and the Tax Cuts and Jobs Act, a specific catalyst that benefited this cohort relative to their international peers!

The Dollar Spot Index, which tracks the value of the greenback versus other major developed market currencies? Down between the 2016 and 2020 presidential elections. Oh, what about the Bloomberg Dollar Spot Index, which also includes emerging-market currencies like the Mexican peso and Chinese offshore yuan, which got smacked on the 2016 results? Also down from November 8, 2016, through November 3, 2020.

Then there are US stocks. Yes, these outperformed the MSCI World between Trump’s election win and Biden’s, as they did between Trump’s win and Biden’s after that, and during both of Obama’s terms. You have to go back to George Bush’s win over John Kerry to find a time when US stocks underperformed their global counterparts from one presidential race through the next.

US stocks over their global peers isn’t a really Trump trade; it’s a tech trade.

The S&P 500 has outperformed for a long time primarily due to the outsize earnings power of established and emergent tech giants.

While that profitability was boosted by tax cuts, Big Tech was not one of the key beneficiaries of the TCJA. The yawning gap between the growth in forward-earnings estimates for Nasdaq 100 (which is even more tech-heavy than the S&P 500) compared to the MSCI ACWI between the 2016 and 2020 elections is a story of operational excellence and global footprints.

Fiscal policy, trade policy, regulatory policy, all of that certainly matters for markets. But sometimes (dare I say, oftentimes), there are bigger forces at play, or markets are simply unable to trade the same thematic catalyst for years on end — unless it’s a major factor underpinning incremental increases in profitability.

So-called “Trump trades” are much more a “reaction-to-Trump-winning trades” than they have been durable, investable themes. I guess there’s a reason why they call them “Trump trades” and not “Trump investments.”

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.